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Introduction: Low-dose computed tomography (LDCT) is
used for screening for lung cancer (LC) in high-risk patients
in the United States. The deﬁnition of high risk and the
impact of frequent false-positive results of low-dose
computed tomography remains a challenge. DNA methyl-
ation biomarkers are valuable noninvasive diagnostic tools
for cancer detection. This study reports on the evaluation of
methylation markers in plasma DNA for LC detection and
discrimination of malignant from nonmalignant lung
disease.
Methods: Circulating DNA was extracted from 3.5-mL
plasma samples, treated with bisulﬁte using a commer-
cially available kit, puriﬁed, and assayed by real-time po-
lymerase chain reaction for assessment of DNA methylation
of short stature homeobox 2 gene (SHOX2), prostaglandin E
receptor 4 gene (PTGER4), and forkhead box L2 gene
(FOXL2). In three independent case-control studies these
assays were evaluated and optimized. The resultant assay, a
triplex polymerase chain reaction combining SHOX2,
PTGER4, and the reference gene actin, beta gene (ACTB),
was validated using plasma from patients with and without
malignant disease.
Results: A panel of SHOX2 and PTGER4 provided promising
results in three independent case-control studies examining
a total of 330 plasma specimens (area under the receiver
operating characteristic curve ¼ 91%–98%). A validation
study with 172 patient samples demonstrated signiﬁcant
discriminatory performance in distinguishing patients with
LC from subjects without malignancy (area under the
curve¼ 0.88). At a ﬁxed speciﬁcity of 90%, sensitivity for LC
was 67%; at a ﬁxed sensitivity of 90%, speciﬁcity was 73%.
Conclusions: Measurement of SHOX2 and PTGER4 methyl-
ation in plasma DNA allowed detection of LC anddifferentiation of nonmalignant diseases. Development of a
diagnostic test based on this panel may provide clinical
utility in combination with current imaging techniques to
improve LC risk stratiﬁcation.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
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Introduction
Lung cancer (LC) remains one of the world’s most
common and deadliest forms of cancer.1 Screening with
low-dose computed tomography (LDCT) has been shown
to reduce LC mortality.2 Consequently, most U.S. medical
societies recommend screening with LDCT for certain
high-risk groups deﬁned mainly by age and a history of
intense smoking.3 When the original deﬁnition for a
positive screen from the United States–based National
Lung Screening Trial is used, LDCT performance suffersJournal of Thoracic Oncology Vol. 12 No. 1: 77-84
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which 96% have been determined to be false positives.4
As a consequence, the NELSON trial used a substantially
different deﬁnition of a positive screening result, which
led to a 10-fold decrease in the positive rate (2.7%),
reducing the proportion of false positives to 60% at the
expense of some reduction in sensitivity for LC detec-
tion.5,6 The need for better deﬁnition of the screening-
eligible population led to risk assessment models
developed from large trials.7,8 Similarly, algorithms for
management of so-called intermediate nodules have
been published.9–11 Because of the imperfections of each
of these methods, there is an ongoing quest for sensitive
and reliable biomarkers with the potential to comple-
ment current cancer risk assessments.12
The epigenetic events occurring at early stages of
carcinogenesis are a source of biomarkers.13 Aberrant
DNA methylation has been extensively described as a
means to aid in the detection of cancer, speciﬁcally, in
specimens that are amenable for minimal invasive
sampling.14 Only recently, DNA methylation–based bio-
markers have been successfully incorporated into
commercially available in vitro diagnostic (IVD) devices
approved by U.S. Food and Drug Administration for use
in cancer screening.15,16 For colorectal cancer screening
in stool, a multitarget stool DNA test combined the in-
formation of a fecal immunochemical assay for human
hemoglobin, mutations in the KRAS gene, and the DNA
methylation markers bone morphogenic protein 3 gene
(BMP3) and NDRG family member 4 gene (NDRG4).17,18
Screening for colorectal cancer in a simple blood draw
was made possible with real-time polymerase chain re-
action (PCR) assessment of methylated Septin9 DNA
derived from plasma.19 Both of these methods have been
validated in extensive prospective screening trials.20–22
In LC methylated short stature homeobox 2 gene
(SHOX2) DNA has been described as a valuable
biomarker in several research studies. Elevated SHOX2
methylation was associated with detection of LC in
bronchial aspirates, pleural effusions, and blood
plasma.23–25 Consequently, an IVD intended as a diag-
nostic adjunct to existing clinical and pathological pa-
rameters was developed and validated on bronchial
aspirate specimens. An additional clinical application of
the biomarker SHOX2 was the determination of LC stage
via assessment of SHOX2 positivity of lymph nodes.26
Also, the potential of SHOX2 DNA methylation for
monitoring the response to chemotherapy has been
published recently.27
From the perspectives of the patient and the clinician,
the use of simple blood draw as a primary sample is
most appealing independent of the clinical application
potential. Such a liquid biopsy is easily performed during
routine clinical, whereas tissue biopsies are invasiveand potentially erroneous for difﬁcult-to-reach areas of
the lung. Therefore, we have investigated further the
potential of SHOX2 and two additional methylation
markers, forkhead box L2 gene (FOXL2) and prosta-
glandin E receptor 4 gene (PTGER4), for use as a
noninvasive, blood plasma–based diagnostic tool to
differentiate patients with LC from healthy subjects
and patients with nonmalignant disease of the lung.
Here we report on three independent case-control
studies used to identify a minimal set of biomarkers
with high sensitivity for LC and develop in parallel an
assay format suited for an IVD product. Finally, we
report on a validation study that includes patients with
LC as well as patients with a variety of nonmalignant
lung diseases.Materials and Methods
Subjects
The patient samples were either material collected
over the course of several months by commercial part-
ners (ProteoGenex Inc., Soﬁa Bio LLC) or leftover mate-
rial from previously conducted clinical trials in colon
cancer.21,22 More speciﬁcally, patients with lung disease
(LC and benign disease cases) were collected under the
same protocol at clinical sites in Bulgaria by Soﬁa Bio,
LLC, or in Russia and the United States by ProteoGenex,
Inc. The included healthy controls were collected at
clinical sites in the United States. Study participants
provided informed consent and all involved institutions
adhered to the local ethical guidelines.
For three sequential training studies samples were
randomly chosen from a collection of a total of 118 LC
cases and 212 healthy control subjects. These LC cases
covered all major histological types and a broad range of
stages (Table 1). The ﬁrst small pilot study (study 1)
comprised 10 LC cases and 20 control subjects. The
remaining 300 samples were randomized into 23 pro-
cessing batches. Study 2 used the ﬁrst 12 batches, which
comprised a total of 151 samples (59 LC cases). Study 3
used the remaining 11 batches, which contained 149
samples (49 LC cases). The validation study was con-
ducted with 72 healthy controls, 50 patients with
nonmalignant lung disease, and 50 patients with LC.
These patients with LC were a random subset from pa-
tients in studies 2 and 3 with a second plasma aliquot
available that was restricted to cases from the provider
(Soﬁa Bio, LLC), which also provided the 50 nonmalig-
nant lung disease samples.
Diagnosis of lung disease (malignant or nonmalig-
nant) was provided by the participating institutions. The
nonmalignant diseases were mainly asthma, chronic
obstructive pulmonary disease, and pneumonia (Table 2).
Figure 1 displays details of the sample disposition.
Table 1. Patient Characteristics for Studies 1 to 3
Patients Median Age (Range), y Sex (% male) Clinical Categories
Lung cancer (n ¼ 117) 64 (38 – 80) 77 Histological Subtype (n ¼ 117 )
Adeno Squamous Other SCLC
46 58 8 5
Stage (n ¼ 113a)
0 / I II III IV
26 21 42 24
Healthy patients (n ¼ 212) 61 (50 – 83) 27
aFour subjects with unknown stage.
Adeno, adenocarcinoma; Squamous, squamous cell carcinoma.
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mation on histological type and disease stage. Control
subjects were self-declared to be healthy as there was no
speciﬁc assessment for lung disease as part of their study
inclusion. Common demographic information was limited
to age and sex. Smoking history was available for patients
with LC and most of the patients with nonmalignant lung
disease but for only 36 of the healthy controls.
Blood Sampling, Sample Preparation, and DNA
Methylation Analysis
At all institutions, blood sampling, and plasma prep-
aration were performed according to the same protocol
by trained staff.28 Speciﬁcally, blood was drawn in 10-
mL BD Vacutainer ethylenediaminetetraacetic acid
tubes (BD Biosciences, San Jose, CA). Plasma was pre-
pared by a double-spin procedure within 4 hours after
blood draw. Plasma was stored frozen at –80C and kept
frozen during shipment on dry ice to the testing
laboratory.
All plasma samples had a bar code as their only
identiﬁer. Thus, the clinical group (LC or control) of the
sample was masked to the laboratory personnel con-
ducting the experiments.Table 2. Patient Characteristics for Validation Study
Patients Median Age (Range), y Sex (%
Lung cancer (n ¼ 117) 63 (43 – 80) 77
Benign disease (n ¼ 50) 68 (50 – 83) 62
Healthy patients (n ¼ 72) 60 (49 – 80) 50
aThirty-six subjects with unknown smoking status.
Adeno, adenocarcinoma; Squamous, squamous cell carcinoma; COPD, chronic oAt the testing site plasma samples were thawed and
processed in batches together with positive and negative
workﬂow controls using the Epi proColon Plasma Quick
Kit according to the respective instructions for use.28
Brieﬂy, circulating DNA was extracted from 3.5 mL of
plasma by utilizing magnetic particles. Thereafter, the
DNA was converted in a bisulﬁte reaction. After puriﬁ-
cation, bisulﬁte-converted DNA (bisDNA) was eluted in
60 mL and ready for use in real-time PCR.
The sequence of three training studies was conducted
to evaluate and develop suitable combinations of
methylation markers and respective real-time PCR as-
says. All target gene PCR assays used methylation-
unspeciﬁc primer oligonucleotides (length 17–25 base
pairs) and a blocker oligonucleotide (length 26–35 base
pairs) to suppress the ampliﬁcation of unmethylated
target sequences.29 Hydrolysis probes speciﬁc for the
methylated target sequence were designed for PCR
detection on ﬂuorescence channels FAM, Texas Red, and
VIC. The PCR conditions (volumes, cycling program, and
threshold settings) were essentially those detailed in the
instructions for use of Epi proColon.28
For study 1, real-time PCR assays were designed for
three methylation markers, FOXL2, PTGER4, and SHOX2.male) Clinical Categories
Histological Subtype (n ¼ 50 )
Adeno Squamous Other SCLC
18 25 7 -
Stage (n ¼ 50)
0 / I II III IV
12 11 16 11
Disease Group (n ¼ 50)
Asthma COPD Pneumonia Other
5 18 11 16
Smoking Status (n ¼ 36a)
Smoker Nonsmoker
12 24
bstructive pulmonary disease.
Sample acquired / allocated for training studies (n = 330)
• lung cancer cases (n = 118)
• healthy controls (n = 212)
(Pilot) Study  #1 (n = 30)
• lung cancer cases (n = 10)
• healthy controls (n = 20)
Study  #2 (n = 151)
• lung cancer cases (n = 59)
• healthy controls (n = 92)
Study  #3 (n = 149)
• lung cancer cases (n = 49)
• healthy controls (n = 100)
Randomized
ACTB valid results (n = 151)
• 2 x FOXL2 (12μL) 
• 2 x PTGER4 (12μL)
• 2 x SHOX2 (12μL)
ACTB valid results (n = 148)
no amplificaƟon (n = 1)
• 4 x PTGER4 (12μL)
• 4 x SHOX2 (12μL)
ACTB valid results (n = 30)
• 2 x FOXL2 (8μL) 
• 2 x PTGER4 (8μL) 
• 2 x SHOX2 (8μL) 
DNA extracted from 3.5 mL plasma, bisulfite converted, and purified
Samples allocated to ValidaƟon study (n = 172)
• lung cancer cases (n = 50)
• non-malignant disease (n = 50)
• healthy controls (n = 72)
ACTB valid results (n = 172)
• 3 x PTGER4 (15μL) 
• 3 x SHOX2 (15μL)
DNA extracted from 3.5 mL
plasma,
bisulfite converted, and purified
Figure 1. Sample disposition, study setup, and polymerase chain reaction (PCR) assay formats. Boxes in the bottom line
indicate number of valid results, number of PCR replicates, and bisDNA input volume (in parenthesis) per PCR assay. For more
details, see Materials and Methods section. ACTB, actin, beta gene; FOXL2, forkhead box L2 gene; PTGER4, prostaglandin E
receptor 4 gene; SHOX2, short stature homeobox 2 gene.
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bisDNA input volume. For study 2, two duplex assays
were designed, the ﬁrst comprising methylation
markers FOXL2 and PTGER4 and the second comprising
marker SHOX2 and ACTB as an internal reference assay.
Both assays were run in PCR duplicates with 12 mL of
bisDNA input. For study 3, the marker FOXL2 was
dropped and a triplex assay for PTGER4/SHOX2/ACTB
was designed. The triplex PCR assay was then run in
quadruplicate with 12 mL of bisDNA input. Finally, the
validation study used an optimized version of the
triplex assay with 15 mL of bisDNA input run in tripli-
cate. Figure 1 displays details of the study setup. The
total reaction volume for all PCR assay studies was 30
mL. All assays were run on the Applied Biosystems 7500
FAST Real-Time PCR System (Applied Biosystems,
Foster City, CA).Data Analysis
Real-time PCR data were analyzed using the
Sequence Detection Software v1.4 21 CFR Part 11
Module (Thermo Fisher Scientiﬁc, Waltham, MA) with
appropriate settings for assay thresholds and baselinewindow resulting in a cycle threshold (Ct) value per
assay for each PCR well.
For each sample the minimal Ct value (minCt)
aggregated over PCR replicates per PCR assay repre-
sented the respective measurement. During studies 1
through 3 simple classiﬁers were built by combining the
assay results (minCt) through logistic regression. In the
validation study, analysis was conducted by applying the
trained model to the validation data.
Receiver operating characteristic (ROC) and the area
under the ROC curve (AUC) were analyzed using the R
environment (Version 3.1.2) (R Foundation for Statistical
Computing, Vienna, Austria).30
Results
Pilot study 1 was conducted with a set of three
research PCR assays. Because this pilot study provided
excellent discrimination of the LC group from the con-
trols (AUC ¼ 0.98 [Fig. 2A]), the assays were developed
further into duplex PCR assays to allow for more efﬁ-
cient use of the bisDNA in PCR in a follow-up study. This
assay format was used in study 2, which was conducted
to evaluate the three-marker panel for its ability to
Figure 2. Receiver operating characteristic and area under the curve (AUC) analysis of pilot study 1 (AUC ¼ 0.98) (A), study 2
(AUC ¼ 0.91) (B), and study 3 (AUC ¼ 0.95) (C).
January 2017 SHOX2/PTGER4 DNA Methylation Marker Panel 81differentiate patients with LC from healthy subjects. The
59 LC cases included there represented all major histo-
logical types of LC and a broad distribution of stages (IA
to IV). On the basis of a logistic regression model using
the minCt aggregation of the data, the marker panel
demonstrated signiﬁcant discriminatory power (AUC ¼
0.91 [Fig. 2B]). Detailed analysis led to the hypothesis
that the marker FOXL2 could be dropped from the panel
without signiﬁcant loss of performance. This hypothesis
was tested in study 3, which contained 49 LC samples
among the 149 samples tested. Here, a single LC sample
did not amplify efﬁciently in PCR analysis and was
excluded from data analysis. Before conduct of study 3
the PCR assay format was changed to a triplex assay
containing PTGER4, SHOX2, and ACTB as the ﬁnal
conﬁguration. Optimized use of the bisDNA volume was
achieved through this development. The substantial size
of study 3, as well as the observed discriminatory power
of the two-marker panel (AUC ¼ 0.95 [Fig. 2C]), provided
a convincing argument for reduction of the marker
panel’s complexity. The case and control groups differed
substantially with regard to their sex distribution but
were similar with regard to age (Table 1). Comparison of
a regression model including PTGER4, SHOX2, and sex as
predictors with a model including sex only conﬁrmed the
substantial discriminatory power of the methylation
panel (p < 0.0001, likelihood ratio test).
Thereafter, the data from study 2 and 3 were
collapsed and used to train a classiﬁer by ﬁtting a logistic
regression model based on minCt-values. The trained
model was used to analyze the data from the validation
set, which comprised 50 LC cases and 122 subjects with
or without a nonmalignant lung disease. The case and
control groups were similar with respect to their median
age, and sex bias was substantially smaller than in the
training set (Table 2). The results of the ROC analysis for
the model are displayed in Figure 3A for both the
training set and the validation set. Performance of themodel in the validation set was close to the previous
results (AUC ¼ 0.88 versus AUC ¼ 0.93). At a ﬁxed
speciﬁcity of 90%, sensitivity for LC was 67%; at a ﬁxed
sensitivity of 90%, speciﬁcity was 73%. A detailed
analysis of the data revealed good performance for
comparison of the LC group with 50 patients with
nonmalignant disease (AUC ¼ 0.86 [Fig. 3B]) as well as
with the healthy controls (AUC ¼ 0.91 [Fig. 3C]). The
nonmalignant disease group and the healthy controls
were not different on the basis of their classiﬁer values
(AUC ¼ 0.58, p ¼ 0.15) (Fig. 3D). A ﬁnal comparison was
conducted in 36 healthy subjects with documented
smoking history. The classiﬁer did not distinguish the
group of 12 smokers from the remaining 24 individuals
(AUC ¼ 0.56).Discussion
This study demonstrates that assessment of DNA
methylation markers in blood plasma provides a very
reliable diagnostic method. Of 502 plasma specimens
processed in total over the course of four studies, 501
(99.8%) provided a valid result. Only a single instance of
an invalid sample occurred. The two-marker panel
demonstrated high discriminatory power to differentiate
patients with LC from healthy subjects in training studies
(AUC ¼ 0.93). This panel was validated in a study
incorporating patients with serious nonmalignant lung
diseases such as chronic obstructive pulmonary disease
into the control group. At the same time, improvements
in the PCR assay format were implemented. The reli-
ability of the approach is demonstrated by the results of
the validation study (AUC ¼ 0.88). There was no sub-
stantial performance loss observed despite the fact that
more than 40% of cases in the control group were
nonmalignant disease cases.
However, generalizability of the results of the vali-
dation study may be limited as the samples from
Figure 3. Receiver operating characteristic and area under the curve (AUC) analysis of validation study: (A) Lung cancer (LC)
versus all controls for training (AUC ¼ 0.93) and validation study (AUC ¼ 0.88), (B) LC versus nonmalignant disease (AUC ¼
0.86), (C) LC versus healthy controls (AUC ¼ 0.91), (D) nonmalignant disease versus healthy controls (AUC ¼ 0.58).
82 Weiss et al Journal of Thoracic Oncology Vol. 12 No. 1diseased patients were collected by a single provider. In
an attempt to mitigate the risk of reporting a singular
observation, leftover specimens of study 2 were assessed
for concentration of four proteins commonly reported as
LC biomarkers (carcinoembryonic antigen, cytokeratin
19 fragment, cancer antigen 125, and carbohydrate an-
tigen 19-9)31 by a commercial service provider. The
protein marker panel was used to benchmark the result
of the methylation biomarkers. Figure 4 displays the
performance of this protein panel together with the
two-marker methylation panel (SHOX2/PTGER4) in a
side-by-side comparison. For this sample set, methyl-
ation information (AUC ¼ 0.91) outperforms protein
information (AUC ¼ 0.79) with a statistically signiﬁcant
difference (p ¼ 0.004).
A number of different types of plasma biomarkers
have recently been explored as aids in the diagnostic
work-up of patients with LC.32 Two laboratory-developedtests are currently available in the United States. One
11-protein classiﬁer for management of lung nodules
(Xpressys [Integrated Diagnostics, Inc., Seattle, WA])
demonstrated consistently diagnostic information of
approximately 10% (Youden’s index33 ¼ Sensitivity þ
Speciﬁcity – 1 z 10%).34–36 The performance results
for a panel of autoantibodies for screening of high-risk
patients, EarlyCDT-Lung (Oncoimmune, Ltd., Notting-
ham, United Kingdom), have been recently conﬁrmed
in a routine clinical setting (Youden’s indexz 30%).37,38
on different sets of microRNAs (miRNAs), promising
results with a Youden’s index of approximately 65%
have been reported for both a 34-miRNA classiﬁer in
serum39 and a 24-miRNA signature classiﬁer in plasma.40
The performance of the SHOX2/PTGER4marker panel
as observed in the validation set (Youden’s index z
60%) appears to be competitive with results of other
published methods. Used as a reﬂex test for LDCT
Figure 4. Comparison of protein (area under the curve
[AUC] ¼ 0.79) and methylation (AUC ¼ 0.91) marker panel.
The difference in the AUCs was statistically signiﬁcant (p
value ¼ 0.004).
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excellent sensitivity, the test has reasonably high speci-
ﬁcity that would lead to a substantial reduction of the
false-positive rate of LDCT. Adopted in contrast to very
high speciﬁcity, the test may even be useful as a mini-
mally invasive screening test directing patients to
screening with LDCT. However, more clinical data are
needed to make a fair assessment of the strengths and
weaknesses of a DNA methylation–based approach.
In conclusion, the result of this research validates the
potential of the PTGER4/SHOX2 methylation marker
panel as a minimally invasive diagnostic method to
discriminate between patients with and without malig-
nant lung disease. Used as a complementary tool to
current screening methods it may prove advantageous
for selection of LDCT screening eligible individuals. Pa-
tients at increased risk on the basis of life history,
symptoms, or ﬁndings in LCDT may eventually beneﬁt
from the information provided by a conﬁrmatory
assessment based on PTGER4/SHOX2 methylation re-
sults. However, these clinical uses need to be validated in
future clinical trials.
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